Pioneering endogenous T-cell therapy for cancer treatments
Immunotherapy, which stimulates the patient’s own immune system to attack cancer, has shown promise in treating a variety of cancer...
MD Anderson faculty members awarded at ASCO Annual Meeting
For their role in transforming cancer care, three MD Anderson faculty received the American Society of Clinical Oncology’s Special...
Matching targeted therapies to gene mutations improves...
Matching targeted therapies to tumor-specific gene mutations across tumor types improved survival in patients with advanced cancer,...
Drug may benefit urinary tract cancer...
In recent years, five new immunotherapy drugs have been approved to treat patients diagnosed with urinary cancer. But the drugs, which held promise for replacing standard chemotherapy treatment, shrank tumors in only 15 to 20 percent of patients.
An international Phase II trial led by MD Anderson researchers may provide an alternative. The trial showed that treatment with the oral FGFR inhibitor erdafitinib (ERDA) was well-tolerated...
Could a pill replace chemotherapy for some patients?
In a small Phase II study of early-stage breast cancer patients with BRCA 1 and 2 mutations, researchers found that more than half of...
Researcher found a way to analyze the DNA of individual...
Understanding evolution within cancer cells is a longtime interest for Nicholas Navin, Ph.D., an associate professor of Genetics and...
PARP inhibitor shows benefit for small cell lung cancer...
In a randomized, Phase II trial led by researchers at MD Anderson, adding the PARP inhibitor veliparib to a standard chemotherapy...
8 researchers join ranks of Sabin Family Fellows
Eight MD Anderson researchers have been selected as the newest class of Andrew Sabin Family Fellows. As part of the Andrew Sabin...